Case report shows liver function improvement and fibrosis regression in a patient on parenteral nutrition, indicating lipid emulsion's role.
Up to 65% of patients receiving parenteral nutrition (PN) have intestinal failure–associated liver disease (IFALD) and ~25% will have fibrosis on biopsy. First‐generation lipid injectable emulsions (ILEs) are considered a greater risk factor for IFALD compared with newer formulations. We describe a case report of an adult patient with intestinal failure receiving PN who had improvement of liver function tests (LFTs) and regression of fibrosis on liver biopsy following a switch from 100% soybean oil (SO) ILE to SO, medium‐chain triglyceride, olive oil, and fish oil ILE. This supports the only other existing adult case report in the literature to date, which showed histological improvement but no improvements in LFTs.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: